Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H22N2 |
Molecular Weight | 278.3914 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C(=C/CN2CCCC2)\C3=CC=CC=N3
InChI
InChIKey=CBEQULMOCCWAQT-WOJGMQOQSA-N
InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
Molecular Formula | C19H22N2 |
Molecular Weight | 278.3914 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Triprolidine is a first generation histamine H1 antagonist, which in combination with codeine phosphate and pseudoephedrine hydrochloride is sold under brand name TRIACIN-C. TRIACIN-C is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16105724
Curator's Comment: Known to be CNS penetrant in bovine. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22629251 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TRIACIN-C Approved UseTriacin-C is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. Launch Date1985 |
|||
Palliative | TRIACIN-C Approved UseTriacin-C is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. Launch Date1985 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2355108/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIPROLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31.22 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2355108/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIPROLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2355108/ |
2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIPROLIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis. | 1975 Jan |
|
Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene. | 1994 Sep 1 |
|
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. | 1995 Aug 18 |
|
A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain. | 2000 Jan 3 |
|
Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. | 2001 Apr 2 |
|
Increased histidine decarboxylase expression during in vitro monocyte maturation; a possible role of endogenously synthesised histamine in monocyte/macrophage differentiation. | 2001 Aug |
|
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. | 2002 Jul |
|
Histamine inhibits atrial myocytic ANP release via H2 receptor-cAMP-protein kinase signaling. | 2003 Aug |
|
Molecular characterization of specific H1-receptor agonists histaprodifen and its Nalpha-substituted analogues on bovine aortic H1-receptors. | 2003 May |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro. | 2005 Nov |
|
Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. | 2006 Apr |
|
Involvement of histaminergic receptor mechanisms in the stimulation of NT-3 synthesis in astrocytes. | 2011 Jun |
Patents
Sample Use Guides
Adults and children 12 years and older: 2 teaspoonfuls (10 mL) every 4 to 6 hours, not to exceed 8 teaspoonfuls (40 mL) in 24 hours.
Children 6 to under 12 years: 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 4 teaspoonfuls (20 mL) in 24 hours.
Children 2 to under 6 years: ½ teaspoonful (2.5 mL) every 4 to 6 hours, not to exceed 2 teaspoonfuls.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16105724
In vitro experiments were conducted using Sweetana-Grass (Navicyte) vertical diffusion cells to evaluate the effect of directionality, donor concentration and pH on the permeation of hydroxyzine and triprolidine across excised bovine olfactory mucosa. These studies demonstrated that the Jm-s (mucosal-submucosal flux) and Js-m (submucosal-mucosal flux) of hydroxyzine and triprolidine across the olfactory mucosa were linearly dependent upon the donor concentration without any evidence of saturable transport. Hydroxyzine inhibited the efflux of P-gp substrates like etoposide and chlorpheniramine across the olfactory mucosa. Both hydroxyzine and triprolidine reduced the net flux (Js-m-Jm-s) of etoposide with IC50 values of 39.2 and 130.6 microM, respectively. The lipophilicty of these compounds, coupled with their ability to inhibit P-gp, enable them to freely permeate across the olfactory mucosa. Despite the presence of a number of protective barriers such as efflux transporters and metabolizing enzymes in the olfactory system, lipophilic compounds such as hydroxyzine and triprolidine can access the CNS primarily by passive diffusion when administered via the nasal cavity.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:19:58 GMT 2023
by
admin
on
Fri Dec 15 15:19:58 GMT 2023
|
Record UNII |
2L8T9S52QM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548164
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
||
|
WHO-VATC |
QR06AX07
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
||
|
WHO-ATC |
R06AX07
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB11323MIG
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
DB00427
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
TRIPROLIDINE
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
2763
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
DTXSID3023718
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
207-627-0
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
1228
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL855
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
84116
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
C61992
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
100000076950
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
2L8T9S52QM
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
10849
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
D014311
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
2L8T9S52QM
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
5282443
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
486-12-4
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
6316
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
m11192
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
502
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY | |||
|
Triprolidine
Created by
admin on Fri Dec 15 15:19:58 GMT 2023 , Edited by admin on Fri Dec 15 15:19:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |